ICS |
Inhaled Corticosteroid |
GERD |
Gastroesophageal Reflux Disease |
OSA |
Obstructive Sleep Apnea |
PEF |
Peak Expiratory Flow |
LABA |
Long-Acting Beta2-Agonist |
GINA |
Global Initiative for Asthma |
FeNO |
Fractional Exhaled Nitric Oxide |
T2 |
Type 2 |
IL |
Interleukin |
IgE |
Immunoglobulin E |
FDA |
Food and Drug Administration |
EMA |
European Medicines Agency |
AIFA |
Agenzia Italiana Del Farmaco (Italian Medicines Agency) |
Q4W |
Every Four Weeks |
Q2W |
Every Two Weeks |
ACQ-7 |
Asthma Control Questionnaire 7 |
FEV1 |
Forced Expiratory Volume in 1 Second |
FVC |
Forced Vital Capacity |
EF25–75% |
Forced Expiratory Flow 25–75% |
Th2 |
T-helper 2 (Cells) |
T2-high |
Type 2 High (Phenotype) |
T2-low |
Type 2 Low (Phenotype) |
IL-5 |
Interleukin-5 |
RCT |
Randomized Controlled Trial |
C-ACT |
Childhood Asthma Control Test |
OFC |
Oral Food Challenge |
NOAEL |
No Observed Adverse Effect Level |
BDP |
Beclometasone Dipropionate |
PK |
Pharmacokinetics |
PD |
Pharmacodynamics |
TSLP |
Thymic Stromal Lymphopoietin |
IL-13 |
Interleukin-13 |
JAK |
Janus Kinase |